Literature DB >> 20952561

Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years.

Paula González1, Allan Hildesheim, Ana Cecilia Rodríguez, Mark Schiffman, Carolina Porras, Sholom Wacholder, Alfonso García Piñeres, Ligia A Pinto, Robert D Burk, Rolando Herrero.   

Abstract

BACKGROUND: Cervical human papilloma virus (HPV) detection increases after menopause, but its determinants need clarification.
METHODS: In a case-control study nested within a 10,049 women cohort, we evaluated women 45 to 75 years old who acquired HPV infection and were HPV positive 5 to 6 years after enrollment (N = 252), and HPV-negative women as matched controls (N = 265). Detailed sexual behavior and cellular immune response were investigated. Odds ratios (OR) and attributable fractions were estimated.
RESULTS: Women with 2+ lifetime partners had 1.7-fold (95% CI = 1.1-2.7) higher risk than monogamous women, with similar findings if their partners had other partners. Women with 2+ partners after last HPV-negative result had the highest risk (OR = 3.9; 95% CI = 1.2-12.4 compared with 0-1 partners). Weaker immune response to HPV-16 virus-like particles increased risk (OR = 1.7; 95% CI = 1.1-2.7 comparing lowest to highest tertile). Among women with no sexual activity in the period before HPV appearance, reduced immune response to phytohemagglutinin was the only determinant (OR = 2.9; 95% CI = 0.94-8.8). Twenty-one percent of infections were explained by recent sexual behavior, 21% by past sexual behavior, and 12% by reduced immune response.
CONCLUSIONS: New infections among older women may result from sexual activity of women and/or their partners or reappearance of past (latent) infections possibly related to weakened immune response. IMPACT: HPV infections among older women are associated with current and past sexual exposures and possibly with immune senescence. The risk of cancer from these infections is likely to be low but could not be fully evaluated in the context of this study. ©2010 AACR.

Entities:  

Mesh:

Year:  2010        PMID: 20952561      PMCID: PMC3703390          DOI: 10.1158/1055-9965.EPI-10-0645

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  28 in total

1.  Regression analysis of correlated binary outcomes.

Authors:  C F Sheu
Journal:  Behav Res Methods Instrum Comput       Date:  2000-05

2.  The analysis of stratified multiple responses.

Authors:  Ivy Liu; Thomas Suesse
Journal:  Biom J       Date:  2008-02       Impact factor: 2.207

Review 3.  Age-specific prevalence of infection with human papillomavirus in females: a global review.

Authors:  Jennifer S Smith; Amy Melendy; Rashida K Rana; Jeanne M Pimenta
Journal:  J Adolesc Health       Date:  2008-10       Impact factor: 5.012

4.  Epidemiology of HPV infection among Mexican women with normal cervical cytology.

Authors:  E Lazcano-Ponce; R Herrero; N Muñoz; A Cruz; K V Shah; P Alonso; P Hernández; J Salmerón; M Hernández
Journal:  Int J Cancer       Date:  2001-02-01       Impact factor: 7.396

5.  Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica.

Authors:  R Herrero; A Hildesheim; C Bratti; M E Sherman; M Hutchinson; J Morales; I Balmaceda; M D Greenberg; M Alfaro; R D Burk; S Wacholder; M Plummer; M Schiffman
Journal:  J Natl Cancer Inst       Date:  2000-03-15       Impact factor: 13.506

6.  Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.

Authors:  Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Concepción Bratti; Mark E Sherman; Diane Solomon; Diego Guillén; Mario Alfaro; Jorge Morales; Martha Hutchinson; Hormuzd Katki; Li Cheung; Sholom Wacholder; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2010-02-15       Impact factor: 13.506

7.  Comparisons of HPV DNA detection by MY09/11 PCR methods.

Authors:  Philip E Castle; Mark Schiffman; Patti E Gravitt; Hortense Kendall; Stacy Fishman; Huali Dong; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz; John E Schussler; Robert D Burk
Journal:  J Med Virol       Date:  2002-11       Impact factor: 2.327

8.  Risk of female human papillomavirus acquisition associated with first male sex partner.

Authors:  Rachel L Winer; Qinghua Feng; James P Hughes; Sandra O'Reilly; Nancy B Kiviat; Laura A Koutsky
Journal:  J Infect Dis       Date:  2008-01-15       Impact factor: 5.226

9.  Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,.

Authors:  M Concepción Bratti; Ana C Rodríguez; Mark Schiffman; Allan Hildesheim; Jorge Morales; Mario Alfaro; Diego Guillén; Martha Hutchinson; Mark E Sherman; Claire Eklund; John Schussler; Julie Buckland; Lidia A Morera; Fernando Cárdenas; Manuel Barrantes; Elmer Pérez; Thomas J Cox; Robert D Burk; Rolando Herrero
Journal:  Rev Panam Salud Publica       Date:  2004-02

10.  Prevalence and determinants of HPV infection among Colombian women with normal cytology.

Authors:  M Molano; H Posso; E Weiderpass; A J C van den Brule; M Ronderos; S Franceschi; C J L M Meijer; A Arslan; N Munoz
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more
  34 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

2.  Point: cervical cancer screening guidelines should consider observational data on screening efficacy in older women.

Authors:  Alison S Rustagi; Aruna Kamineni; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2013-08-21       Impact factor: 4.897

3.  Sinecatechins Ointment, 15% for the Treatment of External Genital and Perianal Warts: Proceedings of an Expert Panel Roundtable Meeting.

Authors:  Gary Goldenberg; Maida Taylor; Brian Berman; Mark Kaufmann; William Abramovits; Joshua Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2016-03-01

4.  Low risk of type-specific carcinogenic HPV re-appearance with subsequent cervical intraepithelial neoplasia grade 2/3.

Authors:  Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Concepción Bratti; Mark E Sherman; Diane Solomon; Diego Guillén; Mario Alfaro; Jorge Morales; Martha Hutchinson; Li Cheung; Sholom Wacholder; Robert D Burk
Journal:  Int J Cancer       Date:  2012-02-28       Impact factor: 7.396

Review 5.  Human papillomavirus: what every provider should know.

Authors:  Britt K Erickson; Ronald D Alvarez; Warner K Huh
Journal:  Am J Obstet Gynecol       Date:  2012-09-14       Impact factor: 8.661

Review 6.  The known unknowns of HPV natural history.

Authors:  Patti E Gravitt
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

Review 7.  Menopause in Latin America: Symptoms, attitudes, treatments and future directions in Costa Rica.

Authors:  T D Locklear; B J Doyle; A L Perez; S M Wicks; G B Mahady
Journal:  Maturitas       Date:  2017-07-27       Impact factor: 4.342

Review 8.  The immune system in menopause: pros and cons of hormone therapy.

Authors:  Mimi Ghosh; Marta Rodriguez-Garcia; Charles R Wira
Journal:  J Steroid Biochem Mol Biol       Date:  2013-09-13       Impact factor: 4.292

9.  A cohort effect of the sexual revolution may be masking an increase in human papillomavirus detection at menopause in the United States.

Authors:  Patti E Gravitt; Anne F Rositch; Michelle I Silver; Morgan A Marks; Kathryn Chang; Anne E Burke; Raphael P Viscidi
Journal:  J Infect Dis       Date:  2012-12-12       Impact factor: 5.226

10.  Prevalence and risk factors for oncogenic human papillomavirus infections in high-risk mid-adult women.

Authors:  Rachel L Winer; James P Hughes; Qinghua Feng; Long Fu Xi; Shu-Kuang Lee; Sandra F O'Reilly; Nancy B Kiviat; Laura A Koutsky
Journal:  Sex Transm Dis       Date:  2012-11       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.